Clinical Trial Update: Safety Study of Rituximab (Rituxan®) in Chronic Urticaria [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports safety findings from Phase 1/2 studies of rituximab in chronic urticaria, which has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urticaria

Drugs mentioned

• Rituxan (rituximab)

Snippet

Sponsor: Johns Hopkins University | Conditions: Urticaria | Phase 1, Phase 2 | Status: TERMINATED